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BACKGROUND: Waist circumference (WC) thresholds derived from western populations continue to be used in sub-Saharan Africa
(SSA) despite increasing evidence of ethnic variation in the association between adiposity and cardiometabolic disease and
availability of data from African populations. We aimed to derive a SSA-speciﬁc optimal WC cut-point for identifying individuals at
increased cardiometabolic risk.
METHODS: We used individual level cross-sectional data on 24 181 participants aged ⩾ 15 years from 17 studies conducted
between 1990 and 2014 in eight countries in SSA. Receiver operating characteristic curves were used to derive optimal WC cut-
points for detecting the presence of at least two components of metabolic syndrome (MS), excluding WC.
RESULTS: The optimal WC cut-point was 81.2 cm (95% CI 78.5–83.8 cm) and 81.0 cm (95% CI 79.2–82.8 cm) for men and women,
respectively, with comparable accuracy in men and women. Sensitivity was higher in women (64%, 95% CI 63–65) than in men
(53%, 95% CI 51–55), and increased with the prevalence of obesity. Having WC above the derived cut-point was associated with a
twofold probability of having at least two components of MS (age-adjusted odds ratio 2.6, 95% CI 2.4–2.9, for men and 2.2, 95% CI
2.0–2.3, for women).
CONCLUSION: The optimal WC cut-point for identifying men at increased cardiometabolic risk is lower (⩾81.2 cm) than current
guidelines (⩾94.0 cm) recommend, and similar to that in women in SSA. Prospective studies are needed to conﬁrm these cut-points
based on cardiometabolic outcomes.
International Journal of Obesity (2018) 42, 487–494; doi:10.1038/ijo.2017.240
INTRODUCTION
The rapidly increasing burden of cardiometabolic disease in sub-
Saharan Africa (SSA) requires effective cardiometabolic disease
prevention and management strategies.1–3 Detection of increased
cardiometabolic risk in apparently healthy individuals is essential
for timely intervention to help prevent or delay progression to
disease.4 Given the resource constraints in SSA, there is a need for
low cost and easily accessible tools for identifying individuals at
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increased risk to facilitate early initiation of lifestyle modiﬁcation
and/or treatment as part of cardiometabolic disease prevention
and management programmes.
Anthropometric indices are cheap and simple tools used for
assessment of overweight and obesity in clinical practice and have
been shown to be good predictors of cardiovascular risk.5 In
particular, raised waist circumference (WC), a marker of central
obesity, is used independently or in conjunction with other risk
factors to predict cardiometabolic disease.6 Compared with other
anthropometric measures, WC is the cheapest, easiest to
determine and, in some populations, the strongest anthropo-
metric cardiometabolic risk predictor.7
The WC thresholds or cut-points derived from populations of
European ancestry were recommended for assessing cardiometa-
bolic risk in Africans in the absence of sufﬁcient data from African
populations.8,9 These cut-points have continued to be used in SSA
despite increasing availability of data from the region and growing
evidence of ethnic variation in the relationship between adiposity
and cardiometabolic risk.6,10 Ethnic differences in the relationship
between adiposity and cardiometabolic risk mean that the
optimal WC threshold indicating increased cardiometabolic risk
in SSA populations are likely to be different from those
determined in western populations. Indeed, recent studies have
indicated different WC thresholds in some SSA populations.11,12
However, these studies have been characterised by relatively small
sample size and highly homogeneous populations, mostly from
South Africa. This has limited the adoption of their recommenda-
tions across SSA. We, therefore, aimed to derive an optimal WC
threshold relevant for identifying individuals at increased cardio-
metabolic risk across the region using pooled individual
participant data.
MATERIALS AND METHODS
Data sources and inclusion criteria
This study utilises data collated as part of the African Partnership for
Chronic Disease Research (APCDR) (www.apcdr.org), an initiative that
facilitates collaborative epidemiological and genomic research of chronic
diseases across SSA. Speciﬁcally, this study draws on individual participant
data collated from studies in SSA to assess the relationship between
anthropometric variables and cardiometabolic disease risk. This is referred
to subsequently in this paper as the ‘Anthropometry Study’. The following
procedures were used to identify appropriate data sets to be included in
the study. First, a literature search was conducted to identify published
population-based studies that have collected data on anthropometric
measurements and other cardiometabolic risk factors until December
2014. Second, all countries that had conducted STEPwise approach to
chronic disease risk factor Surveillance surveys (STEPS) up to December
2014 were identiﬁed through a search of the literature and enquiry from
the Department of Chronic Diseases and Health Promotion at the World
Health Organisation (WHO) in Geneva. The lead investigators involved in
these studies were contacted and invited to contribute to individual
participant data for pooled analyses. Additional data sets were identiﬁed
through communication with the initial investigators contacted.
Supplementary Table S1 shows a summary of the data collated. Only
individuals aged 15 years or older, not pregnant, and who had data on all
ﬁve components of metabolic syndrome (MS) were included in our
analysis. MS was deﬁned according to the International Diabetes
Federation (IDF) 2009 Joint Interim Statement (JIS) modiﬁed to allow for
determination of glycaemic status using glycated haemoglobin (HbA1c) in
the absence of fasting blood glucose.6,13,14
Data collection
We used data collected on anthropometric measurements and other
cardiometabolic risk factors in the Anthropometry Study. In the majority of
the studies, anthropometric measurements were taken according to WHO
guidelines using standardised and calibrated equipment.15 Blood samples
for measurement of glucose and lipids were drawn after 8–10 h overnight
fast except in one study that collected non-fasting samples for lipids and
HbA1c.16 Details of measurements are shown in Supplementary Table S2.
Deﬁnitions
We used the IDF harmonised criteria for MS to deﬁne cardiometabolic risk
factors with a slight modiﬁcation allowing for use of HbA1c to determine
glycaemic status in the absence of fasting glucose.6 Raised WC was deﬁned
as WC ⩾ 94 cm (men) and WC ⩾ 80 cm (women); raised blood pressure (BP)
as BP ⩾ 130/85 mm Hg or use of antihypertensive medication; low plasma
high-density lipoprotein cholesterol (HDL-C) cholesterol as HDL-C
o1.0 mmol l− 1 in men and HDL-C o1.3 mmol l− 1 in women. Raised
plasma triglycerides (TG) was deﬁned as TG41.7 mmol l− 1 and raised
fasting blood/plasma glucose (FG) as FG⩾ 5.6 mmol l− 1 or treatment for
diabetes, or HbA1c⩾ 5.7% in the absence of fasting glucose.6,13,14 Raised
body mass index (BMI) was deﬁned as BMI ⩾ 25 kg m−2; obesity as BMI
⩾ 30 kg m−2; raised waist-to-hip ratio (WHR) as WHR41.0 (men) and
WHR40.85 (women); raised waist-to-height ratio (WHtR) as WHtR40.5;
raised total plasma cholesterol (TC) as TC45.0 mmol l− 1; and raised plasma
low-density lipoprotein cholesterol (LDL-C) as LDL-C43.0 mmol l− 1.17–19
Statistical analysis
The full data set (obtained by merging data sets from all the contributing
studies) for this study was split into two parts; one for derivation of optimal
cut-points for anthropometric markers of adiposity, and one for validation
of the derived cut-points. One study from each of the regions East Africa
(Kenya, Tanzania and Uganda), West Africa (Nigeria and Benin) and
Southern Africa (South Africa) was randomly selected for the validation
data set while the remaining studies were used for derivation. This resulted
in distribution of 18/82% of the full data set between the validation and
derivation data sets, respectively.
For each of the data sets (full, derivation and validation), descriptive
statistics, including means and prevalence of continuous and categorical
variables, respectively, were calculated and presented with 95% con-
ﬁdence intervals (95% CI) for men and women separately, and for both
sexes combined. Estimates of prevalence were adjusted to the WHO world
population using the direct method to facilitate direct comparison
between studies.20
Non-parametric receiver operating characteristics curve analyses were
conducted using the derivation data set to assess the ability of
anthropometric markers of adiposity (WC, BMI, WHR and WHtR) to detect
the presence of at least two components of MS excluding WC, which aligns
with previous studies.12 The area under the receiver operating character-
istics curve (AUC) and the corresponding 95% CI were used to summarise
the discriminatory power of each marker and the optimal cut-point was
determined as the value corresponding to the Youden index. We used
likelihood ratio tests to compare AUC of the other anthropometric markers
with AUC for WC. The performance of the derived cut-points in terms of
sensitivity, speciﬁcity, positive predictive value (PPV) and negative
predictive value was then assessed in the validation data set and
compared with thresholds currently recommended for adiposity in this
population.
Sensitivity analyses were performed to assess whether the optimal WC
cut-point depends on the prevalence of obesity; whether the exclusion of
low HDL-C, because of its very high prevalence (age-adjusted 56%)
affected the discriminatory power of WC; and whether the sensitivity of the
derived cut-point for WC varied with age. Additionally, we assessed the
relative probability of having at least two components of MS between
individuals with a WC equal to or greater than the derived cut-point and
individuals with a WC below the cut-point. We also compared WC cut-
points determined by the Youden Index with WC cut-points based on
inﬂexion points at which the odds ratio of having at least two components
of MS suddenly increases. Furthermore, we conducted sensitivity analyses
to assess whether the inclusion of adolescents (15–18 years) had an impact
on derived cut-points for WC by comparing cut-points derived with and
without this age group.
All analyses were performed in STATA 13.1 (Stata, College Station,
TX, USA).
RESULTS
The APCDR Anthropometry study data set comprises 41 studies
with a total of 86354 (59% women) (Figure 1) individuals aged
1–115 years. Of these, we included in our analyses 24181 (59%
women) from 17 studies in eight countries (Benin, Nigeria,
Democratic Republic of Congo, Uganda, Kenya, Tanzania, South
Optimal threshold of WC for detecting cardiometabolic risk
K Ekoru et al
488
International Journal of Obesity (2018) 487 – 494
Africa and Seychelles) who were ⩾ 15 years of age and had data
on all of WC, BP, plasma TG, plasma HDL-C and fasting blood/
plasma glucose or HbA1c. Table 1 summarises the characteristics
of individuals in the current study. The overall mean age was 41.9
years (41.7–42.1) with only a slight difference between women
and men (women: 42.2 years (42.0–42.5) versus men: 41.5 years
(41.2–41.8)). Compared with men, women also had a signiﬁcantly
higher mean BMI, WC, hip circumference, WHtR, diastolic BP, TC,
LDL-C, FG and HbA1c, while there was no sex difference in mean
TG and HDL-C. The mean WC was 79.0 cm (range 49–180 cm)
among men, and 80.9 cm (range 53–171 cm) in women.
Conversely, men had a higher mean WHR and systolic BP. Further,
there was no sex difference in age-adjusted prevalence of raised
TG, while the prevalence of low HDL-C was higher in women than
in men. The age-adjusted prevalence of MS was 20% (20–21%)
with a signiﬁcantly higher prevalence in women (26% (26–27%))
than in men (11% (11–12%)), and in older age groups than
younger age groups (Supplementary Figure S1).
Similarly, the prevalence of individual cardiometabolic risk
factors was higher in women and older individuals
(Supplementary Figure S2). The age-adjusted prevalence of
abdominal obesity determined by raised WC was 35% (34–35%)
overall, but 50% (49–50%) in women and only 12% (11–12%) in
men. The age-adjusted prevalence of total body obesity based on
BMI (⩾30 kg m−2) was 15% (14–15%) overall, 6% (6–7%) in men
and 23% (22–23%) in women. The age-adjusted prevalence of
raised blood pressure was 40% (40–41%) overall and only slightly
higher in men than in women. Low HDL cholesterol was the most
common type of dyslipidaemia with an overall age-adjusted
prevalence of 57% (56–57%), 40% (39–41%) in men and 68%
(67–68%) in women. Raised TG was the least common with an
age-adjusted prevalence of 13% (13–13%) with no signiﬁcant sex
differences. The age-adjusted prevalence of raised blood glucose
was 17% (16–17%) and was also not signiﬁcantly different
between men and women (Table 1).
Table 2 gives the results from the derivation data set of receiver
operating characteristics curve analyses for identifying the optimal
cut-points of selected adiposity measures for detecting the
presence of at least two components of MS (excluding WC). The
optimal cut-point for WC was 81.2 cm (78.5–83.8 cm) in men; this
was not statistically signiﬁcantly different from 81.0 cm
(79.2–82.8 cm) derived for women. The corresponding AUCs were
similar between men and women, 0.66 (0.65–0.68) in men and
0.66 (0.65–0.67) in women. Compared with each of the other
anthropometric markers of adiposity (BMI, WHR and WHtR), WC
had a greater or equal accuracy of predicting individuals with at
least two MS components (Supplementary Figure S3). The
sensitivity of the derived WC cut-point within the derivation data
set was low but greater in women 64% (63–65%) than in men 53%
(51–55%).
Table 3 shows the performance of the derived cut-points of WC
and other anthropometric markers in the validation data set. The
derived cut-point for WC in men (⩾81.2 cm) had a sensitivity of
60% (54–65%), which was higher than the sensitivity in the
derivation data set 53% (51–55%). However, this sensitivity was
higher than the sensitivity of 31% (26–36%) of the current cut-
point (⩾94.0 cm). Generally, among men, derived cut-points
showed higher sensitivities than currently recommended cut-
points for all anthropometric indices of adiposity. Among women,
the derived WC cut-point (⩾81.0 cm) had a sensitivity of 67% (64–
70%). This was higher than the sensitivity in the derivation data
set (64%, (63–65%)), but slightly lower than the sensitivity of the
currently recommended threshold (⩾80.0 cm, sensitivity: 71% (68–
74%)). The derived cut-point for WHtR (40.54) had a signiﬁcantly
lower sensitivity in the validation data set (55% (52–58%)) than the
currently recommended cut-point (40.50) for women. However,
the sensitivity (66% (62–69%)) of the derived cut-point for WHR
(40.83) was higher than the sensitivity (54% (50–57%)) of the
currently recommended cut-point (40.85) (Table 3). The PPV
associated with the derived WC cut-points were 46% (44–49%) for
women and 35% (32–39%) for men. The negative predictive value
was high in both men 86% (84–88%) and women 77% (74–79%).
As expected, the PPV increased with the prevalence of at least two
components of MS across studies. Among women, the PPV ranged
from 21 to 80% when the prevalence of the presence of at least
two components of MS was 15 and 72%, respectively
(Supplementary Table S3). In men, the PPV ranged from 19 to
76% when the prevalence of the presence of at least two
components of MS was 10% and 48%, respectively.
Sensitivity analyses
Results of sensitivity analyses are shown in Supplementary Figures
S4–S9. They show a positive correlation between prevalence of
obesity and the optimal WC cut-point (Supplementary Figures S4
and S5); a higher AUC when low HDL-C is excluded as a
component of MS (Supplementary Figure S6), as well as age-peaks
for the sensitivity of the derived optimal WC cut-point in men and
women (Supplementary Figure S7). Additionally, individuals with
WC greater than or equal to the derived cut-point were two times
more likely to have at least two components of MS (adjusting for
age) (men, OR 2.6, 95% CI 2.4–2.9; women, OR 2.2, 95% CI 2.0–2.3),
compared with individuals with WC below the cut-point
(Supplementary Figure S8). Further, the inﬂexion point-based
WC cut-point (Figure 2) was similar to the cut-point based on
Youden Index for women (80.8 cm compared with 81.0 cm 95% CI
79.2–82.8, respectively) but different for men (84.8 cm compared
with 81.2 cm 95% CI 78.5–83.8, respectively). However the
sensitivity of the cut-point of 84.8 cm was only 38%, much lower
than 58% for the cut-point of 81.2 cm, among men. In addition,
the derived optimal WC cut-point excluding adolescents aged
15–18 years (6.9% of the derivation data set) was 81.6 cm
(95% CI 78.8–84.4 cm) for men and 81.2 cm (95% CI
78.9–83.5 cm), which were not signiﬁcantly different from the
cut-points derived from data including adolescents.
DISCUSSION
In this pooled analysis of 24181 participants, we have derived WC
cut-points relevant for identifying men and women at increased
cardiometabolic risk in populations across SSA. The derived
Figure 1. Data sets used for derivation and validation of cut-points
of adiposity markers to deﬁne metabolic syndrome.
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Table 1. Participant characteristics in the full data set (N 24 181: men 9729, women 14 452)
Characteristicsa Nb (men/women) Men Women All
Mean (95% CI)
Age (years)* 9729/14 452 41.5 (41.1–41.8) 42.2 (42.0–42.5) 41.9 (41.7–42.1)
WC** 9729/14 452 79.0 (78.8–79.2) 82.1 (81.9–82.3) 80.9 (80.7–81.0)
BMI** 9709/14 426 22.0 (21.9–22.1) 25.2 (25.1–25.3) 24.0 (23.9–24.0)
Hip* 9234/13 933 88.8 (88.6–89.1) 97.5 (97.1–97.8) 94.1 (93.9–94.3)
WHR** 9234/13 933 0.89 (0.89–0.89) 0.85 (0.85–0.85) 0.87 (0.87–0.87)
WHtR** 8919/13 230 0.48 (0.47–0.48) 0.53 (0.52–0.53) 0.51 (0.50–0.51)
SBP** 9535/14 273 125 (124–125) 123 (123–124) 124 (124–124)
DBP** 9703/14 432 77 (77–77) 78 (78–78) 78 (77–78)
TC** 7896/11 422 4.0 (4.0–4.0) 4.2 (4.2–4.2) 4.1 (4.1–4.1)
TGc 9729/14 452 1.00 (0.99–1.02) 0.99 (0.98–1.00) 1.0 (0.99–1.00)
HDL-C 9729/14 452 1.2 (1.2–1.2) 1.2 (1.2–1.2) 1.2 (1.2–1.2)
LDL-C** 6688/10 485 2.2 (2.2–2.2) 2.4 (2.4–2.4) 2.3 (2.3–2.4)
FG** 6693/10 571 5.1 (5.1–5.1) 5.2 (5.2–5.3) 5.2 (5.1–5.2)
HbA1c** 4073/5851 5.3 (5.2–5.3) 5.4 (5.4–5.4) 5.3 (5.3–5.4)
Prevalence % (95% CI)
MS (⩾3 of 5 abnormalities)** 9729/14 452 11 (11–12) 26 (26–27) 20 (20–21)
WC⩾ 94/80 (men/women)** 9729/14 452 12 (11–12) 50 (49–50) 35 (34–35)
BMI⩾ 25** 9709/14 426 19 (19–20) 41 (41–42) 33 (32–33)
BMI⩾ 30** 9709/14 426 6 (5–6) 20 (20–21) 15 (14–15)
WHR41.0/0.85 (men/women)** 9234/13 933 10 (9–11) 45 (44–46) 31 (30–32)
WHtR40.5** 8919/13 230 27 (26–28) 54 (53–55) 43 (43–44)
BP ⩾ 130/85 or use of antihypertensive medication* 9729/14 452 42 (41–43) 39 (38–40) 40 (40–41)
TC45.0** 7896/11 422 21 (20–21) 24 (23–24) 22 (22–23)
TG41.7 9729/14 452 13 (12–14) 13 (13–14) 13 (13–13)
HDL-C o1.0/1.3 (men/women)** 9729/14 452 40 (39–41) 68 (67–68) 57 (56–57)
LDL-C43.0** 6688/10 485 19 (18–20) 24 (23–24) 22 (21–22)
FG45.6 or HbA1c ⩾ 5.7d 9729/14 452 17 (17–18) 16 (16–17) 17 (16–17)
Ever smoked** 6798/9400 24 (23–26) 5 (5–6) 13 (13–14)
Ever consumed alcohol** 4423/6367 51 (49–52) 35 (34–37) 41 (40–42)
Abbreviations: BMI, body mass index (kg m−2); BP, blood pressure (mmHg); CI, conﬁdence interval; DBP, diastolic blood pressure (mmHg); FG, fasting blood/
plasma glucose (mmol l− 1); HbA1c, glycated haemoglobin (%); HDL-C, high-density lipoprotein cholesterol (mmol l− 1); Hip, hip circumference (cm); LDL-C,
low-density lipoprotein cholesterol (mmol l− 1); N, number of participants; SBP, systolic blood pressure (mmHg); TC, total cholesterol (mmol l− 1); TG,
triglycerides (mmol l− 1); WC, waist circumference (cm); WHR, waist-to-hip ratio; WHtR, waist-to-height ratio. aMeans and prevalence are standardised to the
WHO world standard population using the direct method. bThe total of men and women for some characteristics is less than 24 181 because of missing data.
cData are median standardised to the median age in the full data set. dIndividuals with both FG and HbA1c measurements available were classiﬁed using FG.
**Po0.001, *Po0.05 (comparisons are between men and women). Data are mean (95% CI) (except as indicated by b) and prevalence (%) (95% CI) (some CI
limits coincide due to rounding errors).
Table 2. Results of the receiver operating characteristics (ROC) curve analyses for identifying optimal anthropometric cut-points for detecting the
presence of at least two components of MS (excluding WC) in the derivation data set (N 19 880: men 8055, women 11 825)
Anthropometric variable AUC P-valuea for difference in AUC between
index and WC
Cut-point Sensitivity (%) Speciﬁcity (%) Youden index
Overall
WC 0.66 (0.65–0.67) — 81.1 (80.4–81.6) 61 (60–62) 65 (64–66) 0.260
BMI 0.63 (0.62–0.64) o0.001 24.8 (23.9–25.6) 51 (50–52) 70 (70–71) 0.214
WHR 0.56 (0.55–0.57) o0.001 0.87 (0.85–0.89) 51 (50–53) 59 (58–60) 0.103
WHtR 0.65 (0.64–0.66) 0.277 0.51 (0.49–0.53) 53 (52–55) 70 (69–71) 0.234
Men
WC 0.66 (0.65–0.68) — 81.2 (78.5–83.8) 53 (51–55) 73 (72–74) 0.258
BMI 0.64 (0.62–0.65) o0.001 23.2 (22.1–24.3) 48 (46–50) 74 (73–76) (0.220
WHR 0.59 (0.58–0.60) o0.001 0.88 (0.85–0.90) 62 (60–64) 53 (51–54) 0.156
WHtR 0.65 (0.64–0.67) 0.276 0.48 (0.47–0.49) 58 (56–60) 66 (65–68) 0.242
Women
WC 0.66 (0.65–0.67) — 81.0 (79.2–82.8) 64 (63–65) 61 (60–62) 0.251
BMI 0.62 (0.61–0.63) o0.001 25.1 (23.6–26.6) 57 (55–58) 65 (64–66) 0.193
WHR 0.56 (0.55–0.57) o0.001 0.83 (0.81–0.85) 62 (60–63) 49 (48–51) 0.114
WHtR 0.65 (0.64–0.66) o0.001 0.54 (0.53–0.56) 54 (53–56) 69 (68–70) 0.229
Abbreviations: AUC, area under the curve; BMI, body mass index (kg m−2); N, number of participants; WC, waist circumference (cm); WHR, waist hip ratio;
WHtR, waist-to-height ratio. aP-values reported for tests restricted to individuals in which both WC and the anthropometric measure assessed are determined.
Data in brackets are 95% conﬁdence intervals.
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optimal WC cut-point for women is similar to the currently
recommended threshold for Africans (81.0 versus 80.0 cm) but
substantially lower for men (81.2 versus 94.0 cm). The ﬁndings
suggest that current WC guidelines underestimate cardiometa-
bolic risk among African men. Importantly, as a consequence,
current guidelines may underestimate the burden of abdominal
obesity by as much as 7 percentage points in the general
population and 22 percentage points among men in SSA. This
could have wider implications including inadequate resource
allocation for prevention and control of obesity and the initiation
of lifestyle interventions too late in the disease process. This
emphasises the need to cautiously interpret estimates of disease
risk and burden based on indicators derived for a different
population. Therefore, the ﬁndings of this study provide evidence
of the need to undertake prospective studies to establish more
broadly the relationship between cardiometabolic risk factors and
clinical events in SSA.
The markedly lower cut-point for WC (and other markers of
adiposity including BMI, WHR and WHtR) in men highlights ethnic
differences in the relationship between anthropometry, adiposity
and cardiometabolic risk. This cut-point is probably a reﬂection of
a stronger association between WC (a proxy for visceral adiposity)
and cardiometabolic risk among African men compared with men
of European descent from whom the cut-point that was
recommended for SSA was derived.21,22 Similar observations in
Asian populations have been explained by greater visceral
adiposity in Asians compared with Europeans at the same level of
WC.23–25 This explanation is unlikely to hold in the case of African
men as available evidence suggests that populations of African
ancestry (African Americans and Afro-Caribbeans) have less
visceral fat compared with populations of European ancestry at
a given level of WC.26,27 Therefore, other aetiological factors, such
as the impact of exposure to undernutrition (including gestational
exposure to maternal undernutrition) on subsequent weight gain,
adiposity and adipocyte secretion proﬁles, perhaps interacting
with genetic predisposition, may explain a stronger association
between WC and metabolic risk in African populations.8 Further-
more, we found low HDL-C to be the most common cardiometa-
bolic risk factor and raised TG the least common. This is in contrast
to evidence from European populations, where cardiometabolic
risk is characterised by hypertriglyceridaemia, while low TG is a
consistent characteristics of people of African descent in the same
environment.28,29 Thus, our ﬁnding may reﬂect this ethnic
variation in cardiometabolic risk proﬁles and their relationship
with measures of adiposity.
Although previously indicated in smaller, homogeneous African
populations, our study is the largest and the most population-
diverse to demonstrate a lower WC cut-point for identifying men
at increased cardiometabolic risk in SSA compared with men of
European descent.12 Notably, the cut-point derived in our study is
lower than that reported in earlier studies. A possible explanation,
given that WC is not only a reﬂection of subcutaneous and visceral
fat accumulation in the trunk region but also of absolute body
size, would be that our study included younger participants
(adolescents aged 15–18 years) who more likely to have a smaller
absolute body size compared with adults, while the minimum age
in earlier studies was 25 years. However, sensitivity analyses in our
study found no signiﬁcant impact of including adolescents aged
15 years or older. Further, as discussed, the majority of the earlier
reports were from South Africa, where the underlying prevalence
of obesity is much higher relative to our study. The current study
Table 3. Performance of derived cut-points compared with current cut-points in the validation data set (N 4301: men 1674, women 2627)
Anthropometric variable Derived/current index Na Cut-point Sensitivity (%) Speciﬁcity (%) Positive predictive
value (%)
Negative predictive
value (%)
Men
WC Derived 1674 81.2 60 (54–65) 69 (64–72) 35 (32–39) 86 (84–88)
Current 1674 94 31 (26–36) 93 (92–94) 56 (49–63) 83 (81–85)
BMI Derived 1674 23.2 41 (35–46) 79 (77–81) 35 (31–40) 82 (80–85)
Current 1674 25 31 (26–36) 88 (86–89) 41 (35–47) 82 (80–84)
WHR Derived 1373 0.88 65 (60–70) 56 (53–59) 33 (29–36) 84 (81–86)
Current 1373 1 12 (9–16) 98 (97–99) 70 (56–81) 78 (75–80)
WHtR Derived 1671 0.48 57 (52–62) 68 (66–71) 34 (30–38) 85 (83–87)
Current 1671 0.5 50 (44–55) 78 (76–80) 39 (34–43) 85 (82–87)
Women
WC Derived 2627 81 67 (64–70) 58 (56–60) 46.3 (44–49) 77 (74–79)
Current 2627 80 71 (68–74) 54 (52–57) 45 (43–48) 78 (75–80)
BMI Derived 2624 25.1 57 (53–60) 71 (69–73) 51 (48–54) 75 (73–77)
Current 2624 25 59 (56–63) 69 (67–72) 51 (48–54) 76 (74–78)
WHR Derived 2289 0.83 66 (63–69) 47 (45–50) 42 (39–44) 71 (68–74)
Current 2289 0.85 54 (50–57) 61 (58–63) 44 (41–47) 70 (67–72)
WHtR Derived 2626 0.54 55 (52–58) 73 (71–75) 53 (49–56) 75 (73–77)
Current 2626 0.5 71 (68–74) 54 (52–57) 45 (43–48) 78 (75–80)
Abbreviations: BMI, body mass index (kg m−2); N, number of participants; WC, waist circumference (cm); WHR, waist hip ratio; WHtR, waist-to-height ratio. aThe
total of men and women for some indices is less than 4301 because of missing data. Data in brackets are 95% conﬁdence intervals.
Figure 2. Odds ratio of having at least two components of metabolic
syndrome (MS) in each decile (second to tenth) of waist
circumference relative to the ﬁrst decile (number of participants,
19 880: men 8055, women 11 825).
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includes South African cohorts and populations with a low
prevalence of obesity from outside of South Africa. Importantly,
greater variation in urbanisation and lifestyles due to differences
in stages of socio-economic transition in the present study may
also explain some of the observed differences. However, the
optimal WC cut-point for detecting the presence of at least two
components of MS and the optimal cut-point for individual risk
factors among men were broadly similar in the current study with
the exception of raised FG/HbA1c and low HDL which had higher
individual cut-points.
Among women, our ﬁndings suggest that the cut-point
recommended in current guidelines may be appropriate in this
population. This is consistent with the ﬁndings of a previous study
which found no evidence of racial differences in the association
between BMI and WC among women.30 The implication of this is
that current WC guidelines, which are based on BMI among
women of European descent, may be appropriate for women in
SSA. However, we note that studies in populations with a high
prevalence of obesity have reported markedly higher WC cut-
points for men and most particularly women.11,12,31 The explana-
tion for this is not clear, but these data do suggest that in
populations with high levels of obesity, the cardiometabolic
components of MS become prevalent at a higher level of
abdominal obesity than observed in populations with a lower
prevalence of obesity. Additionally, the optimal WC cut-point for
individual risk factors except, as in men, low HDL and raised FG/
HbA1c, was, in contrast with the observation among men,
generally higher than the optimal WC for detecting the presence
of at least two components of MS among women.
Further, our ﬁndings suggest greater utility of WC compared
with other markers of adiposity (BMI, WHR and WHtR) in detecting
the presence of at least two other components of MS. This is
consistent with the growing body of evidence showing that WC,
compared with other anthropometric measures, is a stronger
indicator of visceral adiposity.12,32 In the present study we also
found WC to have the strongest association with the presence of
at least two other cardiometabolic risk factors (raised blood
pressure, components of dyslipidaemia and raised glycaemic
levels) compared with BMI, WHR and WHtR in men and women
(stronger in men than in women). This ﬁnding contrasts with other
studies that have found WHR and WHtR to be more strongly
associated with cardiovascular risk than WC.33,34 These differences
require further evaluation but they highlight the complexity of the
relationship between anthropometric measures, adiposity and
cardiometabolic disease risk. The pathogenesis of cardiometabolic
disease likely involves other environmental and genetic risk
factors whose effects may not be mediated through some
measures of anthropometry.
Another notable ﬁnding from this study is the suggestion of a
common WC cut-point for men and women. Whether this is an
indication of comparable visceral adiposity and cardiometabolic
risk at similar levels of WC in men and women in this population is
not clear. Our data show that men, despite having a four times
lower prevalence of obesity (BMI⩾ 30 kg m−2), have only a slightly
higher prevalence of hypertension relative to women. This
phenomenon has been observed elsewhere and is thought to
be the confounding effect of smoking and alcohol consumption in
men.34,35 Regardless of the underlying mechanism, a common WC
cut-point for men and women may have important implications
for clinical practice and health promotion because it is easier to
formulate a single health message for men and women. To our
knowledge, only one other study has previously reported a
common WC cut-point for men and women.36 Further assessment
of this result in a prospective study in a population of similar
diversity as the present study would help clarify this ﬁnding.
Our ﬁndings also suggest that the optimal WC cut-point and the
associated sensitivity for identifying individuals at increased
cardiometabolic risk may be inﬂuenced by age and BMI. Previous
studies have similarly noted the positive effects of population
mean BMI and WC levels on the optimal waist cut-point for MS
diagnosis.37–39 Furthermore, given the low sensitivity and
speciﬁcity of WC observed in this and previous studies, there
may be need to consider the feasibility of age- and BMI-speciﬁc
cut-points for identifying individuals at increased cardiometabolic
risk.40
The strength of this study is its large sample size and
geographical coverage. With over 24 000 participants drawn from
Central, East, South and West Africa, this study is the largest and
most diverse in terms of populations in SSA, to assess an optimal
cut-point for WC to date. In addition, we validated the derived cut-
points in a separate data set, and the comparable sensitivities and
speciﬁcities observed suggest that the thresholds are reliable and
valid. Further, two methods of determining the optimal cut-point
were used and yielded broadly similar results which increases the
reliability of cut-points derived in this study.
The study has some limitations. First, like cut-points currently in
use, the cut-points derived in this study are based on cross-
sectional data, which precludes examination of the temporality of
the association between raised WC and cardiometabolic risk
factors. This is important because it is possible that the
development of diabetes or hypertension inﬂuences body size.
Second, our analyses have been limited to examining the
association of anthropometric markers of adiposity with cardio-
metabolic risk factors rather than cardiovascular events, diabetes
or mortality. However, even the current WC cut-points (derived
among populations of European ancestry) are based on their
ability to detect overweight and obesity as deﬁned by BMI and not
their relationship with cardiometabolic risk.41 Additionally, the WC
cut-points for individual risk factors (raised TG, HDL-C and fasting
blood glucose) found in our study are similar to those previously
reported in a prospective study of black South African women
indicating that the cut-points we have derived may be acceptable
approximate indicators of future cardiometabolic risk.34 Third, the
HIV and antiretroviral therapy may have inﬂuenced our results.
However such inﬂuences, if any, are likely to be limited to South
Africa where the prevalence of HIV and antiretroviral therapy use
is substantial. Further we used HbA1c to assess dysglycaemia;
however, its use is yet to be validated in populations in SSA where
factors that alter red cell lifecycle such as sickle cell disease and
malaria are prevalent. We also recognise that variation in
measurement of WC between studies due to differences in
equipment and skill of people taking measurements, among
others, might have inﬂuenced the validity of cut-off points derived
in this study. However, the direction of this bias is unclear.
In summary, our ﬁndings indicate that men in SSA are likely to
be at increased cardiometabolic risk at a lower WC threshold than
recommended in current guidelines, while the threshold that was
recommended for women may be appropriate. Thus, current
guidelines could be substantially underestimating abdominal
obesity in men in Africa, which has policy, public health and
health-care implications. This reiterates the importance of
population-speciﬁc anthropometric cut-points that account for
ethnic variation in adiposity and its association with cardiometa-
bolic risk.38 However, there is a need for prospective studies to
clarify the impact of underlying population distribution of obesity
on the optimal WC cut-point and to conﬁrm these cut-points
based on prospective risk of hard cardiometabolic outcomes.
Future efforts in this respect should leverage existing cohorts and
health surveillance systems in SSA.
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